Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00046527 | Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer | PHASE3 | COMPLETED | 460 | — | — | Jun 1, 2001 | - | Jul 13, 2006 | 1 | United States |
| NCT00046514 | ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer | PHASE2 | COMPLETED | 100 | — | — | Jun 1, 2001 | - | Dec 15, 2016 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| ABI-007 | DRUG | - |
Patients will be eligible for this trial if: * Female, non-pregnant, non-lactating, and, if of child-bearing potential, have a negative serum pregnancy test, and use approved contraception * Sixteen years of age or older * Histologically or cytologically confirmed breast cancer (stage III or IV) wi...